BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 23934823)

  • 1. Monthly intravitreal bevacizumab for macular edema after iodine-125 plaque radiotherapy of uveal melanoma.
    Mashayekhi A; Rojanaporn D; Al-Dahmash S; Shields CL; Shields JA
    Eur J Ophthalmol; 2014; 24(2):228-34. PubMed ID: 23934823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The variable efficacy of intravitreal bevacizumab and triamcinolone acetonide for cystoid macular edema due to radiation retinopathy.
    Bakri SJ; Larson TA
    Semin Ophthalmol; 2015 Jul; 30(4):276-80. PubMed ID: 24251435
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravitreal bevacizumab at 4-month intervals for prevention of macular edema after plaque radiotherapy of uveal melanoma.
    Shah SU; Shields CL; Bianciotto CG; Iturralde J; Al-Dahmash SA; Say EAT; Badal J; Mashayekhi A; Shields JA
    Ophthalmology; 2014 Jan; 121(1):269-275. PubMed ID: 24139123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravitreal bevacizumab treatment for radiation macular edema after plaque radiotherapy for choroidal melanoma.
    Mason JO; Albert MA; Persaud TO; Vail RS
    Retina; 2007 Sep; 27(7):903-7. PubMed ID: 17891015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized Trial of Monthly Versus As-Needed Intravitreal Ranibizumab for Radiation Retinopathy-Related Macular Edema: 1-Year Outcomes.
    Schefler AC; Fuller D; Anand R; Fuller T; Moore C; Munoz J; Kim RS;
    Am J Ophthalmol; 2020 Aug; 216():165-173. PubMed ID: 32278771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravitreal bevacizumab and/or macular photocoagulation as a primary treatment for diffuse diabetic macular edema.
    Solaiman KA; Diab MM; Abo-Elenin M
    Retina; 2010; 30(10):1638-45. PubMed ID: 20838357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of two doses of intravitreal bevacizumab (Avastin) for treatment of macular edema secondary to branch retinal vein occlusion: results from the Pan-American Collaborative Retina Study Group at 6 months of follow-up.
    Wu L; Arevalo JF; Roca JA; Maia M; Berrocal MH; Rodriguez FJ; Evans T; Costa RA; Cardillo J;
    Retina; 2008 Feb; 28(2):212-9. PubMed ID: 18301025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion.
    Ding X; Li J; Hu X; Yu S; Pan J; Tang S
    Retina; 2011 May; 31(5):838-45. PubMed ID: 21293319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predicting 1-month response of macular edema to intravitreal bevacizumab from 1-hour response.
    Ma DJ; Park KH; Woo SJ
    Can J Ophthalmol; 2014 Jun; 49(3):267-72. PubMed ID: 24862773
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravitreal anti-VEGF therapy for macular radiation retinopathy: a 10-year study.
    Finger PT; Chin KJ; Semenova EA
    Eur J Ophthalmol; 2016; 26(1):60-6. PubMed ID: 26391167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of intravitreal triamcinolone acetonide versus intravitreal bevacizumab as the primary treatment of clinically significant macular edema.
    Liu Q; Hu Y; Yu H; Yuan L; Hu J; Atik A; Guan M; Li D; Li X; Tang S
    Retina; 2015 Feb; 35(2):272-9. PubMed ID: 25105313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of two doses of intravitreal bevacizumab as primary treatment for macular edema secondary to central retinal vein occlusion: results of the pan American collaborative retina study group at 24 months.
    Wu L; Arevalo JF; Berrocal MH; Maia M; Roca JA; Morales-Cantón V; Alezzandrini AA; Díaz-Llopis MJ
    Retina; 2010; 30(7):1002-11. PubMed ID: 20616679
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of two doses of intravitreal bevacizumab as primary treatment for macular edema secondary to branch retinal vein occlusions: results of the Pan American Collaborative Retina Study Group at 24 months.
    Wu L; Arevalo JF; Berrocal MH; Maia M; Roca JA; Morales-Cantón V; Alezzandrini AA; Díaz-Llopis MJ
    Retina; 2009; 29(10):1396-403. PubMed ID: 19898177
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primary intravitreal bevacizumab for diffuse diabetic macular edema: the Pan-American Collaborative Retina Study Group at 24 months.
    Arevalo JF; Sanchez JG; Wu L; Maia M; Alezzandrini AA; Brito M; Bonafonte S; Lujan S; Diaz-Llopis M; Restrepo N; Rodríguez FJ; Udaondo-Mirete P;
    Ophthalmology; 2009 Aug; 116(8):1488-97, 1497.e1. PubMed ID: 19545900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CHANGES IN CENTRAL CHOROIDAL THICKNESS AFTER TREATMENT OF DIABETIC MACULAR EDEMA WITH INTRAVITREAL BEVACIZUMAB CORRELATION WITH CENTRAL MACULAR THICKNESS AND BEST-CORRECTED VISUAL ACUITY.
    Nourinia R; Ahmadieh H; Nekoei E; Malekifar P; Tofighi Z
    Retina; 2018 May; 38(5):970-975. PubMed ID: 28426622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravitreal bevacizumab for refractory pseudophakic cystoid macular edema: the Pan-American Collaborative Retina Study Group results.
    Arevalo JF; Maia M; Garcia-Amaris RA; Roca JA; Sanchez JG; Berrocal MH; Wu L;
    Ophthalmology; 2009 Aug; 116(8):1481-7, 1487.e1. PubMed ID: 19545901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of natural course, intravitreal triamcinolone, and intravitreal bevacizumab for treatment of macular edema secondary to branch retinal vein occlusion.
    Kwon SI; Kim YW; Bang YW; Lee JY; Park IW
    J Ocul Pharmacol Ther; 2013 Feb; 29(1):5-9. PubMed ID: 23237542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-dose (2.0 mg) intravitreal ranibizumab for recalcitrant radiation retinopathy.
    Finger PT; Chin KJ
    Eur J Ophthalmol; 2013; 23(6):850-6. PubMed ID: 23813109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prophylactic Intravitreal Bevacizumab After Plaque Radiotherapy for Uveal Melanoma: Analysis of Visual Acuity, Tumor Response, and Radiation Complications in 1131 Eyes Based on Patient Age.
    Chang M; Dalvin LA; Mazloumi M; Martin A; Yaghy A; Yang X; Bakhtiari S; Li L; Jennings E; Mashayekhi A; Shields CL
    Asia Pac J Ophthalmol (Phila); 2020; 9(1):29-38. PubMed ID: 31990743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ozurdex(®) reduces the retinal thickness in radiation maculopathy refractory to bevacizumab.
    Tarmann L; Langmann G; Mayer C; Weger M; Haas A; Wackernagel W
    Acta Ophthalmol; 2014 Dec; 92(8):e694-6. PubMed ID: 24739457
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.